Leadership. Empowerment. Development.
LEAD is a 2-day conference designed for women in oncology and hematology. The goal of this conference is to empower women leaders in the hematology and oncology space by providing essential clinical updates, career development, and professional networking. Sessions include discussions on the importance of women’s leadership, career development workshops, and clinical sessions on biomarkers and oncology therapies.
*Program is subject to change prior to conference.
Day 1: October 4, 2019
|
7:00 AM—8:00 AM |
Breakfast and Registration One-on-One Mentoring Sessions |
|
8:00 AM—8:05 AM |
Welcome Remarks and Conference Overview |
|
Plenary Session: The Importance of Women’s Leadership in Healthcare and Oncology |
|
|
8:05 AM – 9:30 AM |
Professional Vignettes and Panel Discussion: Women oncology leaders share their journeys and perspectives on the past and current state of women in healthcare and how they are amplifying women’s voices in oncology Linda Bosserman, MD | City of Hope |
|
9:20 AM – 9:30 AM |
Panel Discussion and Participant Q&A Chair and Session Speakers |
|
Session I: Focused Workshops, Part 1 |
|
|
9:30 AM – 10:15 AM |
Burnout or Balance? Barrett McBride, PhD |
|
10:15 AM – 10:30 AM |
Break |
|
10:30 AM – 11:30 AM |
Panel: Building Your Resiliency and Relationship Success Moderator: Barrett McBride, PhD Charu Aggarwal, MD, MPH | U. of Pennsylvania |
|
11:30 AM – 12:15 PM |
A Social Media Toolkit to Enhance Your Career Moderator: Shikha Jain, MD | Rush U. Medical Center Stephanie Graff, MD | Menorah Medical Center |
|
12:15 PM – 1:30 PM |
Lunch |
|
12:30 PM – 1:30 PM |
Industry Product Theater |
|
Session II: Impact of Emerging Biomarkers on Treatment Selection and Drug Development |
|
|
1:30 PM – 1:50 PM |
The Role of Biomarkers in the Development of PARP Inhibitors Joyce O’Shaughnessy, MD | Texas Oncology |
|
1:50 PM – 2:10 PM |
When Biomarkers Define Indication – MSI, MMR, and Mutations Rachna Shroff, MD | U. of Arizona Cancer Center |
|
2:10 PM – 2:30 PM |
Challenges with Biomarkers in Cancer Drug Development Lauren Byers, MD | MD Anderson |
|
2:30 PM – 2:45 PM |
Panel Discussion and Participant Q&A Chair and Session Speakers |
|
2:45 PM – 3:15 PM |
Break |
|
Session III and IV: Clinical Updates in Immuno-Oncology and Cell-based Therapies |
|
|
3:15 PM – 3:35 PM |
Patient Selection in Frontline Metastatic Lung Cancer Julie Brahmer, MD, MSc | Johns Hopkins Medicine |
|
3:35 PM – 3:55 PM |
CAR T Cell Therapy: New Era of Therapy for B-Cell Malignancies Julie Vose, MD, MBA | U. of Nebraska Medical Center |
|
3:55 PM – 4:15 PM |
Targeted Tumor Treatment with Antibody Drug Conjugates Sarah Hurvitz, MD | UCLA |
|
4:15 PM – 4:35 PM |
Antibody Therapy as an Evolving SOC in Multiple Myeloma Nina Shah, MD | UCSF |
|
4:35 PM – 4:50 PM |
Panel Discussion and Participant Q&A |
|
4:50 PM – 5:25 PM |
Immunotherapy for PD-L1 Positive or MSI-high Cervical Cancer
Claire Friedman, MD | Memorial Sloan Kettering |
|
5:25 PM – 5:45 PM |
Treatment Evolution in Triple Negative Breast Tiffany Traina, MD | Memorial Sloan Kettering |
|
5:45 PM – 6:00 PM |
Panel Discussion and Participant Q&A Chair and Session Speakers |
|
6:00 PM – 7:00 PM |
Evening Networking Reception |
Day 2: October 5, 2019
|
6:30 AM – 7:30 AM |
Sunrise Yoga |
|
8:00 AM – 8:30 AM |
Breakfast One-on-One Mentoring Sessions |
|
Session V: Clinical Updates in Small-Molecule Targeted Inhibitors |
|
|
8:30 AM – 8:50 AM |
CLL: Reaching for Curative Potential Alessandra Ferrajoli, MD | MD Anderson |
|
8:50 AM – 9:10 AM |
Targeted Inhibitors in EGFR-positive Lung Cancer Leora Horn, MD, MSc, FRCPR | Vanderbilt Ingram Cancer Ctr |
|
9:10 AM – 9:30 AM |
Moving Beyond Checkpoint Inhibitors: New Treatment Options in Urothelial Cancer Arlene Siefker-Radtke, MD | MD Anderson |
|
9:30 AM – 9:45 AM |
Panel Discussion and Participant Q&A Chair and Session Speakers |
|
Session VI: Patient Management and Supportive Care in an Era of New Therapies |
|
|
9:45 AM – 10:05 AM |
Financial and Quality of Life Impact of Early Supportive Care Monica Malec, MD | U. of Chicago |
|
10:05 AM – 10:25 AM |
Sexual Health and Fertility After Cancer Treatment for Women Anne Katz, PhD, RN | CancerCare Manitoba |
|
10:25 PM – 10:45 AM |
Redefining Value with Modern Cancer Therapies Debra Patt, MD, MPH, MBA | US Oncology |
|
10:45 AM – 11:00 AM |
Panel Discussion and Participant Q&A Chair and Session Speakers |
|
11:00 AM – 11:20 AM |
Break |
|
Session VII: Focused Workshops, Part 2 |
|
|
11:20 AM – 12:05 PM |
Panel: Building Your Brand Moderator: Nina Shah, MD | UCSF Charu Aggarwal, MD, MPH | U. of Pennsylvania |
|
12:05 PM – 12:50 PM |
Panel: Leaning Into Leadership Opportunities Moderator: Julie Vose, MD, MBA | U. of Nebraska Medical Center Linda Bosserman, MD | City of Hope Leora Horn, MD, MSc, FRCPC | Vanderbilt Ingram Cancer Ctr Jane Meisel, MD | Emory U. Winship Cancer Inst. |
|
12:50 PM – 1:50 PM |
Lunch |
|
12:50 PM – 1:50 PM |
Industry Product Theater |
|
Session VIII: Focused Workshops, Part 3 |
|
|
1:50 PM – 3:20 PM |
Transformational Leadership Margaret Moore, MBA | Wellcoaches Corporation |
|
3:20 PM – 3:50 PM |
Keynote – Future of Women in Oncology Julie Vose, MD, MBA | U. of Nebraska Medical Center |
|
3:50 PM – 4:00 PM |
Award Presentations: Woman Oncologist of the Year and Rising Star Sponsored by Women Leaders in Oncology Closing Remarks and Adjourn |